Silence Therapeutics PLC（SLN）のニュースとイベントSLNSilence Therapeutics PLC

Nasdaq Rebounds Thanks to AI Infrastructure Stocks

The Nasdaq rebounded from last week's losses thanks to dip buying in heavyweight AI infrastructure stocks. The advance follows tech weakness last week, when underwhelming financial results from Anthropic and signs of debt stress among cloud providers, especially CoreWeave, dented demand for speculative positions in the sector.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Anthropic announced plans to commit 5% of its shares to a Public Benefit Fund to enable the company to "pursue our mission in new ways"SpaceXCEO Elon Musk pledged to give one of his SpaceX shares to "every kid in America," adding that "this will be the first of many."Investment bankers have been circling Blue Owl Capital, meeting with its founders to propose a full or partial sale of the business, WSJ saysMicrosofthas withdrawn from a UK data center deal with Nscale, Bloomberg saysCleveland-Cliffsshares are rising after the steel company reported Q3 results that beat expectations2. WALL STREET CALLS:Goldman Sachs upgraded CoreWeaveto BuyAmeriprisedouble downgraded to Underperform at BofA amid retention challengesIntelupgraded to Neutral at JPMorganLongbow downgraded Whirlpool, citing a weakening consumer backdropDatadogupgraded to Outperform at Bernstein3. AROUND THE WEB:Hon Hai Precisionwill pay $727M for a 50% stake in Mitsubishi Electric'sautomotive components unit, Bloomberg saysUberwon its bid to throw out two lawsuits in the UK valued at EUR 340M brought by London black cab drivers and two former private hire companies over allegations on how it obtained a private hire vehicle operating license, Reuters reportsStellantisCEO Ned Curic said the company plans to continue hiring more engineers as the company rolls out new models as part of its turnaround plan, Bloomberg saysMorgan Stanleyhas entered a partnership with Raisin UK, a fintech platform, to provide savings accounts to individuals in the country, Bloomberg reportsQuantinuumsaid it has achieved record-setting results to correct the tendency for "qubits" at the center of a quantum computer to generate errors based on tiny disturbances in their environments, WSJ reports4. MOVERS:Silence Therapeuticsgained after entering an agreement to be acquired by Merck KgaAfor $20 per ADS in cashDisc Medicineincreased after reporting its APOLLO trial of bitopertin met all its primary and secondary endpointsStriverose after announcing it purchased 4,045 bitcoinFervo Energyfell after JPMorgan removed it from its Analyst Focus ListDynex Capitaldeclined after reporting quarterly results5. EARNINGS/GUIDANCE:Nyxoahreported preliminary Q3 results and cut its guidance for FY26Cleveland-Cliffsreported Q3 results, with EPS beating consensusFifth Thirdreported Q3 results and provided guidance for Q4Eos Energyprovided guidance for Q3 and backed its outlook for FY26EquipmentShareraised its outlook for FY26INDEXES:The Dow fell 36.38, or 0.07%, to 51,966.03, the Nasdaq gained 290.85, or 1.11%, to 26,430.89, and the S&P 500 advanced 31.29, or 0.41%, to 7,690.73.

Dow Rises 90.80 Points, Nasdaq Up 453.36 Points

The major averages were higher near noon as a rebound in heavyweight AI infrastructure stocks offset muted movement in broader sectors. The advance follows tech weakness last week, when underwhelming financial results from Anthropic and signs of debt stress among cloud providers, especially CoreWeave, dented demand for speculative positions in the sector.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Anthropic announced plans to commit 5% of its shares to a Public Benefit Fund to enable the company to "pursue our mission in new ways"SpaceXCEO Elon Musk pledged to give one of his SpaceX shares to "every kid in America," adding that "this will be the first of many."Investment bankers have been circling Blue Owl Capital, meeting with its founders to propose a full or partial sale of the business, WSJ saysMicrosofthas withdrawn from a UK data center deal with Nscale, Bloomberg saysCleveland-Cliffsshares are rising after the steel company reported Q3 results that beat expectations2. WALL STREET CALLS:Goldman Sachs upgraded CoreWeaveto BuyAmeriprisedouble downgraded to Underperform at BofA amid retention challengesIntelupgraded to Neutral at JPMorganLongbow downgraded Whirlpool, citing a weakening consumer backdropDatadogupgraded to Outperform at Bernstein3. AROUND THE WEB:Hon Hai Precisionwill pay $727M for a 50% stake in Mitsubishi Electric'sautomotive components unit, Bloomberg saysUberwon its bid to throw out two lawsuits in the UK valued at EUR 340M brought by London black cab drivers and two former private hire companies over allegations on how it obtained a private hire vehicle operating license, Reuters reportsStellantisCEO Ned Curic said the company plans to continue hiring more engineers as the company rolls out new models as part of its turnaround plan, Bloomberg saysMorgan Stanleyhas entered a partnership with Raisin UK, a fintech platform, to provide savings accounts to individuals in the country, Bloomberg reportsQuantinuumsaid it has achieved record-setting results to correct the tendency for "qubits" at the center of a quantum computer to generate errors based on tiny disturbances in their environments, WSJ reports4. MOVERS:Silence Therapeuticsgains in New York after entering an agreement to be acquired by Merck KgaAfor $20 per ADS in cashDisc Medicineincreases after reporting its APOLLO trial of bitopertin met all its primary and secondary endpointsStrivehigher after announcing it purchased 4,045 bitcoinFervo Energylower after JPMorgan removed it from its Analyst Focus ListDynex Capitalfalls after reporting quarterly results5. EARNINGS/GUIDANCE:Nyxoahreported preliminary Q3 results and cut its guidance for FY26Cleveland-Cliffsreported Q3 results, with EPS beating consensusFifth Thirdreported Q3 results and provided guidance for Q4Eos Energyprovided guidance for Q3 and backed its outlook for FY26EquipmentShareraised its outlook for FY26INDEXES:Near midday, the Dow was up 90.80, or 0.17%, to 52,093.21, the Nasdaq was up 453.36, or 1.73%, to 26,593.40, and the S&P 500 was up 66.01, or 0.86%, to 7,725.45.

Merck KGaA Acquires Silence Therapeutics at $20 per ADS

Merck KGaA (MKGAY) announced its entry into a definitive agreement to acquire Silence Therapeutics plc (SLN). The purchase price of $20 per ADS in cash, with each ADS representing three ordinary shares of Silence Therapeutics, represents an enterprise value of $1.1B and an equity value of approximately $1.3B. The consideration represents an 82% premium to Silence Therapeutics' 30-day volume-weighted average price of $10.99, as of the close of trading on October 16, 2026, the last trading day prior to the transaction announcement. The transaction is subject to satisfaction of customary closing conditions. The transaction, once completed, will add Divesiran - a potentially best-in-class, phase 3-ready siRNA investigational therapy, in development for phlebotomy-dependent polycythemia vera - to Merck KGaA, Darmstadt, Germany's pipeline. Divesiran is dosed subcutaneously once every 3 months. PV is a chronic myeloproliferative neoplasm - a type of rare blood cancer - characterized by the excessive production of red blood cells, which can be associated with a higher rate of death from cardiovascular and thrombotic events. Divesiran is designed to selectively silence TMPRSS6, a gene involved in regulating hepcidin, the body's key regulator of iron metabolism. By increasing hepcidin levels, Divesiran aims to limit iron availability for red blood cell production, helping to control hematocrit levels and potentially reducing the need for frequent therapeutic phlebotomies. Divesiran met its primary endpoint in the Phase 2 SANRECO study with an 88% responder rate versus 19% for placebo (pless than0.0001) and reduced mean phlebotomies to 0.2 per patient versus 2.1 on placebo over weeks 0-36, irrespective of background cytoreductive therapy. Divesiran was observed to be well-tolerated and no new safety findings were observed in the trial. Injection site reactions were infrequent and self-limiting. There were two cases of Grade 1 anemia which were assessed as related to treatment by an investigator. The transaction has been unanimously approved by Silence Therapeutics' Board of Directors and Merck KGaA, Darmstadt, Germany's relevant corporate bodies and is expected to close in the first quarter of 2027, subject to satisfaction of customary closing conditions, including receipt of required regulatory approvals and approval by Silence Therapeutics' shareholders. In connection with the transaction, certain securityholders of Silence Therapeutics holding securities representing approximately 14% of Silence Therapeutics' voting power have entered into a voting and support agreement with Merck KGaA, Darmstadt, Germany, under which the securityholders have agreed among other things, to vote their voting securities of Silence Therapeutics in favor of the transaction. Silence Therapeutics is a UK company, with ADSs, each representing three of its ordinary shares, listed on NASDAQ. As is customary for similar transactions, the transaction will be effected through a UK scheme of arrangement. The planned acquisition will be funded through proceeds from new debt. Silence Therapeutics employs approximately 80 people and operates from locations in the UK, the US and Germany.